Relevance of Circulating Hybrid Cells as a Non-Invasive Biomarker for Myriad Solid Tumors
Dietz, M. S.; Sutton, T. L.; Walker, B. S.; Gast, C. E.; Zarour, L.; Sengupta, S. K.; Swain, J. R.; Eng, J.; Parappilly, M.; Limbach, K.; Sattler, A.; Burlingame, E.; Chin, Y.; Gower, A.; Montoya Mira, J. L.; Sapre, A.; Chiu, Y.-J.; Clayburgh, D. R.; Pommier, S. J.; Cetnar, J. P.; Fischer, J. M.; Jaboin, J. J.; Pommier, R. F.; Sheppard, B. C.; Tsikitis, V. L.; Skalet, A. H.; Mayo, S. C.; Lopez, C. D.; Gray, J. W.; Mills, G. B.; Mitri, Z.; Chang, Y. H.; Chin, K.; Wong, M. H.
Show abstract
AbstractMetastatic progression defines the final stages of tumor evolution and underlies the majority of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable of seeding and growing in distant organ sites contributes to the development of treatment resistant disease. We recently reported the identification of a novel tumor-derived cell population, circulating hybrid cells (CHCs), harboring attributes from both macrophages and neoplastic cells, including functional characteristics important to metastatic spread. These disseminated hybrids outnumber conventionally defined circulating tumor cells (CTCs) in cancer patients. It is unknown if CHCs represent a generalized cancer mechanism for cell dissemination, or if this population is relevant to the metastatic cascade. Herein, we detect CHCs in the peripheral blood of patients with cancer in myriad disease sites encompassing epithelial and non-epithelial malignancies. Further, we demonstrate that in vivo-derived hybrid cells harbor tumor-initiating capacity in murine cancer models and that CHCs from human breast cancer patients express stem cell antigens, features consistent with the ability to seed and grow at metastatic sites. Finally, we reveal heterogeneity of CHC phenotypes reflect key tumor features, including oncogenic mutations and functional protein expression. Importantly, this novel population of disseminated neoplastic cells opens a new area in cancer biology and renewed opportunity for battling metastatic disease. Simple SummaryThere is an incomplete understanding of circulating neoplastic cell populations and the fundamental mechanisms that drive dissemination, immune evasion, and growth --all critical information to more effectively prevent and treat cancer progression. A novel disseminated tumor cell population, circulating hybrid cells, are detected across many cancer types and carry functional tumor-initiating properties. Additionally, circulating hybrid cells are found at significantly higher levels than conventionally defined circulating tumor cells. Our study demonstrates that neoplastic hybrid cells harbor phenotypic and genetic characteristics of tumor and immune cells, display stem features, and are a generalizable phenomenon in solid tumors. Circulating hybrid cells therefore have relevance as a novel biomarker and open a new field of study in malignancy.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Integrative analysis of patient-derived tumoroids and ex vivo organoid modeling of ARID1A loss in bladder cancer reveals therapeutic molecular targets 95%
- UDP-Glucose 6-Dehydrogenase Knockout Impairs Migration and Decreases in vivo Metastatic Ability of Breast Cancer Cells 94%
- Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response 94%
Similar papers in this journal
- Propagated circulating tumor cells uncovers the rople of NFκB and COP1 in metastasis 96%
- Functionally and metabolically divergent melanoma-associated macrophages originate from common bone-marrow precursors 95%
- HIF-dependent expression of creatine kinase brain isoform (CKB) promotes breast cancer metastasis, whereas cyclocreatine therapy impairs invasion and improves the efficacy of conventional chemotherapies 95%
Similar papers in this journal
- Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics 94%
- MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model 94%
- EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas 94%
Similar papers in this journal
- A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 96%
- Polyploid cancer cells reveal signatures of chemotherapy resistance 95%
- Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma 95%
Similar papers in this journal
- Cancer-cell derived S100A11 promotes macrophage recruitment in ER+ breast cancer 95%
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 94%
- Antibody Targeting of B7-H4 Enhances the Immune Response in Urothelial Carcinoma 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.